Botox competitor Daxxify hits $15.4M in Q1 earnings as maker faces trade secrets lawsuit
The second round of revenue numbers is in for Daxxify, Revance Therapeutics’ longer-lasting cosmetic injection set to compete against AbbVie’s Botox.
Revance Therapeutics on Tuesday said the drug, which was approved by FDA in September, brought in $15.4 million in revenue in the first quarter. Revance launched an “early experience program” for Daxxify in December, with a broader commercial launch in March.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters